180 related articles for article (PubMed ID: 12914745)
1. Metabolic effects of GH antagonism in patients with acromegaly.
Trainer PJ
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S152-6. PubMed ID: 12914745
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
3. Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly.
Parkinson C; Trainer PJ
Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S119-23. PubMed ID: 10984267
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
5. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
6. Insights from growth hormone receptor blockade.
Muller AF; van der Lely AJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
[TBL] [Abstract][Full Text] [Related]
7. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
8. The role of growth hormone-receptor antagonism in relation to acromegaly.
Ayuk J; Sheppard MC
Expert Opin Pharmacother; 2004 Nov; 5(11):2279-85. PubMed ID: 15500374
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Drake WM; Parkinson C; Besser GM; Trainer PJ
Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
[TBL] [Abstract][Full Text] [Related]
10. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of pegvisomant for the treatment of acromegaly.
Drake WM; Trainer PJ
Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
[TBL] [Abstract][Full Text] [Related]
12. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
14. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Paisley AN; Trainer P; Drake W
Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
[TBL] [Abstract][Full Text] [Related]
15. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
16. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
17. The place of pegvisomant in the management of acromegaly.
Parkinson C; Trainer PJ
Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
[TBL] [Abstract][Full Text] [Related]
18. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.
Kopchick JJ; Parkinson C; Stevens EC; Trainer PJ
Endocr Rev; 2002 Oct; 23(5):623-46. PubMed ID: 12372843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
